Diabetes and hypertension are the leading causes of endstage renal disease (ESRD). Despite effective medications, the incidence of ESRD is increasing and the associated costs now exceed $15 billion a year. The renal expression of TGF-beta is elevated in hypertension and diabetes and blockade of this pathway decreases renal fibrosis. However, the factors that increase the production of TGF-beta and its role in the initiation of renal disease remain to be determined. In preliminary experiments, we found that inducing the renal formation of 20-HETE or blocking the actions of TGF-beta attenuate the development of renal disease in Dahl S rats. TGF-beta also directly increased the permeability of glomeruli to albumin (Palb) and inhibited the glomerular formation of 20-HETE. Thus, this proposal will evaluate the hypothesis that a deficiency in the renal formation of 20-HETE leads to elevations in glomerular capillary pressure (Pgc) and the renal expression of TGF-beta in Dahl S rats and that the increase in TGF-beta triggers the development of proteinuria and renal disease by increasing Palb.
Specific Aim 1 will determine the relationships between Pgc, the renal expression of TGF-beta, Palb and the development of renal disease and the effects of servocontrol of renal perfusion pressure (RPP) on these responses.
Specific Aim 2 will determine if the reduced production of 20-HETE contributes to the increases in Pgc, TGF-beta and the development of renal disease.
Specific Aim 3 will examine the interactions between TGF-beta and 20-HETE in the regulation of Palb and the mechanism by which TGF-beta inhibits the formation of 20-HETE.
Specific Aim 4 will determine whether Palb is altered early in the development of hypertension and the role of TGF-beta in mediating this response. These studies will employ an array of techniques, ranging from direct measurement of Pgc, LC/MS measurement of 20-HETE and chronic servocontrol of RPP to measurements of Palb and Ca++ in isolated glomeruli. They will also utilize a newly-developed congenic strain of Dahl S rats in which renal 20-HETE levels are elevated and novel inhibitors and antibodies that can manipulate the 20-HETE and TGF-beta pathways in vivo. These translational studies will provide important new information on the role of TGF-beta, 20-HETE and Pgc in the pathogenesis of hypertension-induced renal disease and may be applicable to diabetes and other models of renal disease as well in which TGF-beta and Pgc are also elevated.
Zhang, Chao; Booz, George W; Yu, Qing et al. (2018) Conflicting roles of 20-HETE in hypertension and renal end organ damage. Eur J Pharmacol 833:190-200 |
Shekhar, Shashank; Cunningham, Mark W; Pabbidi, Mallikarjuna R et al. (2018) Targeting vascular inflammation in ischemic stroke: Recent developments on novel immunomodulatory approaches. Eur J Pharmacol 833:531-544 |
Roman, Richard J; Fan, Fan (2018) 20-HETE: Hypertension and Beyond. Hypertension 72:12-18 |
Shekhar, Shashank; Liu, Ruen; Travis, Olivia K et al. (2017) Cerebral Autoregulation in Hypertension and Ischemic Stroke: A Mini Review. J Pharm Sci Exp Pharmacol 2017:21-27 |
Fan, Fan; Roman, Richard J (2017) GPR75 Identified as the First 20-HETE Receptor: A Chemokine Receptor Adopted by a New Family. Circ Res 120:1696-1698 |
Fan, Fan; Roman, Richard J (2017) Effect of Cytochrome P450 Metabolites of Arachidonic Acid in Nephrology. J Am Soc Nephrol 28:2845-2855 |
Shekhar, Shashank; Travis, Olivia K; He, Xiaochen et al. (2017) Menopause and Ischemic Stroke: A Brief Review. MOJ Toxicol 3: |
Zhang, Hui; Falck, John R; Roman, Richard J et al. (2017) Upregulation of 20-HETE Synthetic Cytochrome P450 Isoforms by Oxygen-Glucose Deprivation in Cortical Neurons. Cell Mol Neurobiol 37:1279-1286 |
Fan, Fan; Ge, Ying; Lv, Wenshan et al. (2016) Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology. Front Biosci (Landmark Ed) 21:1427-63 |
Miller, Bradley; Palygin, Oleg; Rufanova, Victoriya A et al. (2016) p66Shc regulates renal vascular tone in hypertension-induced nephropathy. J Clin Invest 126:2533-46 |
Showing the most recent 10 out of 185 publications